Literature DB >> 24444534

Inorganic arsenic trioxide induces gap junction loss in association with the downregulation of connexin43 and E-cadherin in rat hepatic "stem-like" cells.

Pi-Jung Hsiao1, Jo-Chi Jao2, Jin-Lian Tsai3, Wen-Tsan Chang4, Kuo-Shyang Jeng5, Kung-Kai Kuo6.   

Abstract

Chronic exposure to inorganic arsenic trioxide causes tumors of the skin, urinary bladder, lung, and liver. Several cancer initiators and promoters have been shown to alter cell-cell signaling by interference with gap junction intercellular communication (GJIC) and/or modulation of cell adhesion molecules, such as connexin43 (Cx43), E-cadherin, and β-catenin. The aim of this study was to determine whether the disruption of cell-cell interactions occurs in liver epithelial cells after exposure to arsenic trioxide. WB-F344 cells were treated with arsenic trioxide (6.25-50 μM) for up to 8 hours, and gap junction function was analyzed using the scrape-load/dye transfer assay. In addition, the changes in mRNA and protein levels of Cx43, E-cadherin, and β-catenin were determined. A significant dose- and time-dependent decrease in GJIC was observed when WB-F344 cells were exposed to arsenic trioxide (p < 0.05). Consistent with the inhibition of GJIC, cells' exposure to arsenic trioxide resulted in dose- and time-dependent decreases in Cx43 and E-cadherin mRNA expression and protein levels. However, arsenic trioxide did not alter the mRNA or protein levels of β-catenin. In an immunofluorescence study, nuclei were heavily stained with anti-β-catenin antibody, indicating significant nuclear translocation. In this study, we also demonstrated that arsenic trioxide-induced GJIC loss was a reversible process. Taken together, these data support the hypothesis that disruption of cell-cell communication may contribute to the tumor-promoting effect of inorganic arsenic trioxide.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Arsenic toxicity; Carcinogenesis; Liver cancer stem cell

Mesh:

Substances:

Year:  2013        PMID: 24444534     DOI: 10.1016/j.kjms.2013.10.002

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  6 in total

1.  Optimization of Protein-Protein Interaction Measurements for Drug Discovery Using AFM Force Spectroscopy.

Authors:  Yongliang Yang; Bixi Zeng; Zhiyong Sun; Amir Monemian Esfahani; Jing Hou; Nian-Dong Jiao; Lianqing Liu; Liangliang Chen; Marc D Basson; Lixin Dong; Ruiguo Yang; Ning Xi
Journal:  IEEE Trans Nanotechnol       Date:  2019-05-14       Impact factor: 2.570

2.  Influence of gap junction intercellular communication composed of connexin 43 on the antineoplastic effect of adriamycin in breast cancer cells.

Authors:  Guojun Jiang; Shuying Dong; Meiling Yu; Xi Han; Chao Zheng; Xiaoguang Zhu; Xuhui Tong
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

Review 3.  Advances in Liver Cancer Stem Cell Isolation and their Characterization.

Authors:  Lu Liu; Jürgen Borlak
Journal:  Stem Cell Rev Rep       Date:  2021-01-11       Impact factor: 5.739

4.  The Role of E-Cadherin in Maintaining the Barrier Function of Corneal Epithelium after Treatment with Cultured Autologous Oral Mucosa Epithelial Cell Sheet Grafts for Limbal Stem Deficiency.

Authors:  Fawzia Bardag-Gorce; Richard H Hoft; Andrew Wood; Joan Oliva; Hope Niihara; Andrew Makalinao; Jacquelyn Thropay; Derek Pan; Imara Meepe; Kumar Tiger; Julio Garcia; Amanda Laporte; Samuel W French; Yutaka Niihara
Journal:  J Ophthalmol       Date:  2016-09-29       Impact factor: 1.909

Review 5.  Connexins in Cancer: Jekyll or Hyde?

Authors:  Erin E Mulkearns-Hubert; Ofer Reizes; Justin D Lathia
Journal:  Biomolecules       Date:  2020-12-10

6.  Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer.

Authors:  Chao Zhang; Yu-Hui Dai; Shu-Feng Lian; Liang Liu; Ting Zhao; Jun-Ye Wen
Journal:  World J Clin Cases       Date:  2022-09-26       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.